Theravida, Inc.
protein-based therapeutic molecules
- Sector
- Biotech
- Headquarters
- Chapel Hill, NC
- Founded
- 2007
- Latest Form D
- $200K, Feb 2023
- Total capital
- $3.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $3.8M
- 2 Form D · last Feb 2023
- 44 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 10 pending · first 2017
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$200K
- Private capital raisedForm D · SEC · 1st filing$3.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Benjamin F. McGraw IIIResearcherExecutive Officer, DirectorLinked by 4 patents
- Mehdi S. PaborjiResearcherExecutive Officer, DirectorLinked by 3 patents
- Assad S. KazeminyDirectorNamed in SEC Form D filings
- Curtis L. MoExecutive OfficerNamed in SEC Form D filings
- Fred A. MiddletonDirectorNamed in SEC Form D filings
- Nasser J. KazeminyDirectorNamed in SEC Form D filings
Show all 7 people
- Roger S. FlugelExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 17- GrantedMethods And Compositions For Treating HyperhidrosisUSPTOUS 11,779,569
- GrantedMethods And Compositions For Treating HyperhidrosisUSPTOUS 11,185,533
- GrantedPharmaceutical FormulationsUSPTOUS 10,786,457
Show all 17 patent records
- Methods And Compositions For Treating HyperhidrosisOct 10, 2023 · US 11,779,569Granted
- Methods And Compositions For Treating HyperhidrosisNov 30, 2021 · US 11,185,533Granted
- Pharmaceutical FormulationsSep 29, 2020 · US 10,786,457Granted
- Methods And Compositions For Treating HyperhidrosisApr 7, 2020 · US 10,610,519Granted
- Methods and Compositions for Treating HyperhidrosisJun 25, 2019 · US 10,328,057Granted
- Pharmaceutical FormulationsMay 15, 2018 · US 9,968,556Granted
- Methods For The Treatment Of Overactive BladderSep 14, 2017 · Application 15388353Pending
- Combinations Of Solifenacin And Salivary Stimulants For The Treatment Of Overactive BladderAug 29, 2017 · US 9,744,157Granted
- Pharmaceutical Formulations Of PilocarpineApr 17, 2014 · Application 14052302Pending
- Methods For The Treatment Of Overactive BladderNov 7, 2013 · Application 13875087Pending
- Compositions And Methods For The Treatment Of Overactive BladderOct 31, 2013 · Application 13925220Pending
- Pharmaceutical Formulations For The Treatment Of Overactive BladderApplication PCTUS2011031020Pending
- Methods And Compositions For Treating HyperhidrosisApplication PCTUS2016014150Pending
- Pharmaceutical Formulations Of PilocarpineApplication PCTUS2013064596Pending
- Methods For The Treatment Of Overactive BladderApplication PCTUS2013039108Pending
- Methods Of Improving Quality Of SleepApplication PCTUS2011030994Pending
- Pharmaceutical Compositions And Methods For Treating HyperhidrosisApplication PCTUS2022039822Pending
Related companies, and why
- Triveni BioSimilar federal contract value in Biotech · null in contracts
- First Light Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- jCyte, Inc.Similar federal contract value in Biotech · null in contracts
- EpigenCare Inc.Similar federal contract value in Biotech · null in contracts
- Goldenrod Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Okyanos Holdings Co LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .